Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Investors Shouldn't Worry About AstraZeneca's European Woes

By Adria Cimino - Apr 4, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One reason is medical and the other is financial.

In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss the concerns that halted use of AstraZeneca's (AZN 1.05%) coronavirus vaccine in some European countries recently -- and whether the concerns were warranted.

Corinne Cardina: Certain countries have concerns about the AstraZeneca vaccine. Blood clots is what everybody has been talking about. There's been some concern, but maybe it's overhyped. Can you explain why people are concerned about blood clots pertaining to the AstraZeneca vaccine? Should investors be worried?

Adria Cimino: Sure. Well, some vaccinated individuals developed blood clots. Now, we have to keep in mind how many. There were 17 million vaccinated, 15 cases of deep vein thrombosis, 22 cases of pulmonary embolism. This is less than in the general population. If you were to take a general sample of the population, you'd see hundreds of examples of these cases. And there is no link. They have not established any link. Some people in Europe have said this is a political thing: It's like the EU versus the U.K., it's vaccine nationalism. There are all those issues that have come up. Basically, the bottom line is, from a medical perspective, so far, there is no reason to worry. From an investor perspective, there isn't reason to worry either. Shares of the company haven't been very responsive to vaccine news. You have to look at their whole portfolio, and over time, that's how shares of AstraZeneca will gain -- by the whole portfolio, not just one product.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.40 (1.05%) $0.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.